JP2025501307A5 - - Google Patents
Info
- Publication number
- JP2025501307A5 JP2025501307A5 JP2024539913A JP2024539913A JP2025501307A5 JP 2025501307 A5 JP2025501307 A5 JP 2025501307A5 JP 2024539913 A JP2024539913 A JP 2024539913A JP 2024539913 A JP2024539913 A JP 2024539913A JP 2025501307 A5 JP2025501307 A5 JP 2025501307A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cancer
- bispecific molecule
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295681P | 2021-12-31 | 2021-12-31 | |
| US63/295,681 | 2021-12-31 | ||
| PCT/US2022/082628 WO2023130073A2 (en) | 2021-12-31 | 2022-12-30 | Bispecific molecules to target the first cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501307A JP2025501307A (ja) | 2025-01-17 |
| JP2025501307A5 true JP2025501307A5 (https=) | 2026-01-13 |
Family
ID=87000357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024539913A Pending JP2025501307A (ja) | 2021-12-31 | 2022-12-30 | 最初の細胞を標的とする二重特異性分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250051475A1 (https=) |
| EP (1) | EP4456918A4 (https=) |
| JP (1) | JP2025501307A (https=) |
| CN (1) | CN118510539A (https=) |
| AU (1) | AU2022426854A1 (https=) |
| WO (1) | WO2023130073A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085511A1 (en) * | 2023-10-18 | 2025-04-24 | University Of Washington | Systems and methods for polymer-mediated activation of engineered cells |
| WO2025264955A1 (en) * | 2024-06-21 | 2025-12-26 | Tfc Therapeutics, Inc. | Multispecific proteins and related methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI9809391B8 (pt) * | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| US20150094224A1 (en) * | 2010-05-04 | 2015-04-02 | Paul Walfish | Methods for the diagnosis or prognosis of breast cancer |
| US20140030735A1 (en) * | 2011-03-07 | 2014-01-30 | Temple University - Of The Commonwealth System Of Higher Education | Biomarkers of chronic obstructive pulmonary disease |
| EP2825554A2 (en) * | 2012-03-12 | 2015-01-21 | Scaratech Medical AB | Chimeric proteins for treatment of diseases |
| WO2019241216A1 (en) * | 2018-06-14 | 2019-12-19 | Bioatla, Llc | Multi-specific antibody constructs |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| CN114423787B (zh) * | 2019-07-19 | 2025-01-24 | 昂科里斯庞斯公司 | 免疫调节性抗体及其使用方法 |
-
2022
- 2022-12-30 AU AU2022426854A patent/AU2022426854A1/en active Pending
- 2022-12-30 WO PCT/US2022/082628 patent/WO2023130073A2/en not_active Ceased
- 2022-12-30 US US18/719,725 patent/US20250051475A1/en active Pending
- 2022-12-30 CN CN202280087171.5A patent/CN118510539A/zh active Pending
- 2022-12-30 EP EP22917606.0A patent/EP4456918A4/en active Pending
- 2022-12-30 JP JP2024539913A patent/JP2025501307A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth | |
| Guo et al. | Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment | |
| JP2022515318A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2025501307A5 (https=) | ||
| JP2012500814A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2021510736A5 (https=) | ||
| JP2021502810A5 (https=) | ||
| JP2019533475A5 (https=) | ||
| JP2021511811A5 (https=) | ||
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2013166763A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2021528047A5 (https=) | ||
| JP2011505146A5 (https=) | ||
| JP2015529641A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| JP2024504471A5 (https=) | ||
| JP2008508858A5 (https=) | ||
| Wang et al. | NKG2D immunoligand rG7S-MICA enhances NK cell-mediated immunosurveillance in colorectal carcinoma |